Non-Invasive Brain Monitoring Pioneer CoMind Secures Over $100M
October 20, 2025, 9:34 pm
CoMind, a London-based startup, secured over $100 million in funding for its groundbreaking non-invasive brain monitoring technology. Their laser-based system accurately tracks cerebral blood flow and intracranial pressure, eliminating the need for invasive skull drilling. With FDA approval sought by 2027, CoMind aims to transform care for traumatic brain injuries and critical patients, offering a safer, more accessible, and cost-effective alternative to current methods. This innovation promises to democratize vital neurological insights, enhancing patient outcomes and expanding access to critical diagnostics across intensive care units. The technology represents a significant leap in medical diagnostics, backed by substantial investor confidence. The firm plans further AI integration.
London-based startup CoMind leads a revolution in neurological care. It developed a non-invasive brain monitoring technology. This breakthrough eliminates the need for skull drilling. The company recently announced securing over $100 million in total funding. This investment propels CoMind's mission. It promises to transform brain health diagnostics globally.
The latest funding round, a $60 million Series A, was led by Plural. Other investors include Angelini Ventures, LocalGlobe, Octopus Ventures, Crane, Backed VC, and Entrepreneurs First. This substantial backing underscores confidence in CoMind’s disruptive potential. It validates its innovative approach to critical medical challenges.
Existing brain monitoring methods often involve highly invasive procedures. They require drilling a hole into the patient's skull. This introduces significant risks. Complications can occur in up to 15% of cases. Many patients, especially those with traumatic brain injuries (TBIs), receive limited information. This leads to worse treatment decisions and poorer outcomes.
CoMind’s technology offers a critical alternative. It monitors key brain health indicators without any penetration. This reduces patient risk dramatically. It broadens access to vital diagnostic information. Millions of patients previously underserved can now benefit.
The core of CoMind’s system is its advanced laser technology. It employs low-power infrared lasers. These lasers track cerebral blood flow. They monitor intracranial pressure. They also assess autoregulation. These are crucial metrics for patients. They aid those with brain injuries or undergoing complex surgeries.
The technology utilizes optical and signal processing methods. It functions much like LiDAR systems in autonomous vehicles. It scans light through the skull. The light changes color 200,000 times per second. Reflected light then combines with a second laser beam. This process amplifies the signal.
Measurement relies on precise timing. The system tracks the laser’s flight time through brain tissues. It also detects oscillations from red blood cell movement. This allows for accurate measurement of blood flow. It also determines oxygenation levels. These sophisticated developments are possible due to advancements in lasers and graphic processing units. The result is a compact, powerful diagnostic device.
James Dacombe, CoMind’s founder and CEO, started the company at 17. He is now 25. His interest in health tech began early. He studied AI applications in cancer diagnosis. Personal experiences with strokes and dementia among friends and family fueled his resolve. He envisions brain monitoring becoming as routine as blood pressure checks.
The market for such technology is immense. In the U.S. alone, three million patients suffer TBIs annually. Only a small fraction, about 5%, receive an intracranial pressure test. This leaves many untreated with inadequate data. CoMind's non-invasive system opens this vast, unmet need. It provides a safer, more accessible solution.
CoMind aims for U.S. Food and Drug Administration (FDA) approval. It targets this milestone by 2027. This approval will unlock access to the massive intensive care unit (ICU) market. The technology has the potential to become a new standard of care. It promises to improve patient outcomes. It also could significantly reduce healthcare costs.
Beyond current capabilities, CoMind plans further expansion. It will develop an AI platform. This platform will transform sensor data into predictive insights. It will identify complications early. It will enable personalized treatment plans. This integration of AI elevates the technology's potential even further.
Leading medical experts recognize CoMind’s impact. A U.S. surgeon and CoMind board member, Michael Tarnoff, believes the technology can revolutionize care standards. It can lower costs. It can improve patient results substantially. The shift from invasive to non-invasive monitoring marks a paradigm shift.
CoMind’s innovation addresses fundamental healthcare disparities. Invasive procedures are expensive and risky. They are not always available. This limits access. CoMind offers a far more affordable alternative. It makes vital neurological insights accessible to more patients. This democratizes critical care diagnostics.
The company's journey highlights the power of scientific breakthroughs. It shows the impact of engineering in medicine. CoMind stands as a pioneer. It is redefining how brain health is measured. It is fundamentally reshaping neurological treatment.
This European-born startup has global ambitions. Its technology impacts millions. It sets a new benchmark for medical innovation. The future of brain monitoring looks increasingly non-invasive. It looks more insightful. It looks more accessible. CoMind leads this vital evolution.
London-based startup CoMind leads a revolution in neurological care. It developed a non-invasive brain monitoring technology. This breakthrough eliminates the need for skull drilling. The company recently announced securing over $100 million in total funding. This investment propels CoMind's mission. It promises to transform brain health diagnostics globally.
The latest funding round, a $60 million Series A, was led by Plural. Other investors include Angelini Ventures, LocalGlobe, Octopus Ventures, Crane, Backed VC, and Entrepreneurs First. This substantial backing underscores confidence in CoMind’s disruptive potential. It validates its innovative approach to critical medical challenges.
Existing brain monitoring methods often involve highly invasive procedures. They require drilling a hole into the patient's skull. This introduces significant risks. Complications can occur in up to 15% of cases. Many patients, especially those with traumatic brain injuries (TBIs), receive limited information. This leads to worse treatment decisions and poorer outcomes.
CoMind’s technology offers a critical alternative. It monitors key brain health indicators without any penetration. This reduces patient risk dramatically. It broadens access to vital diagnostic information. Millions of patients previously underserved can now benefit.
The core of CoMind’s system is its advanced laser technology. It employs low-power infrared lasers. These lasers track cerebral blood flow. They monitor intracranial pressure. They also assess autoregulation. These are crucial metrics for patients. They aid those with brain injuries or undergoing complex surgeries.
The technology utilizes optical and signal processing methods. It functions much like LiDAR systems in autonomous vehicles. It scans light through the skull. The light changes color 200,000 times per second. Reflected light then combines with a second laser beam. This process amplifies the signal.
Measurement relies on precise timing. The system tracks the laser’s flight time through brain tissues. It also detects oscillations from red blood cell movement. This allows for accurate measurement of blood flow. It also determines oxygenation levels. These sophisticated developments are possible due to advancements in lasers and graphic processing units. The result is a compact, powerful diagnostic device.
James Dacombe, CoMind’s founder and CEO, started the company at 17. He is now 25. His interest in health tech began early. He studied AI applications in cancer diagnosis. Personal experiences with strokes and dementia among friends and family fueled his resolve. He envisions brain monitoring becoming as routine as blood pressure checks.
The market for such technology is immense. In the U.S. alone, three million patients suffer TBIs annually. Only a small fraction, about 5%, receive an intracranial pressure test. This leaves many untreated with inadequate data. CoMind's non-invasive system opens this vast, unmet need. It provides a safer, more accessible solution.
CoMind aims for U.S. Food and Drug Administration (FDA) approval. It targets this milestone by 2027. This approval will unlock access to the massive intensive care unit (ICU) market. The technology has the potential to become a new standard of care. It promises to improve patient outcomes. It also could significantly reduce healthcare costs.
Beyond current capabilities, CoMind plans further expansion. It will develop an AI platform. This platform will transform sensor data into predictive insights. It will identify complications early. It will enable personalized treatment plans. This integration of AI elevates the technology's potential even further.
Leading medical experts recognize CoMind’s impact. A U.S. surgeon and CoMind board member, Michael Tarnoff, believes the technology can revolutionize care standards. It can lower costs. It can improve patient results substantially. The shift from invasive to non-invasive monitoring marks a paradigm shift.
CoMind’s innovation addresses fundamental healthcare disparities. Invasive procedures are expensive and risky. They are not always available. This limits access. CoMind offers a far more affordable alternative. It makes vital neurological insights accessible to more patients. This democratizes critical care diagnostics.
The company's journey highlights the power of scientific breakthroughs. It shows the impact of engineering in medicine. CoMind stands as a pioneer. It is redefining how brain health is measured. It is fundamentally reshaping neurological treatment.
This European-born startup has global ambitions. Its technology impacts millions. It sets a new benchmark for medical innovation. The future of brain monitoring looks increasingly non-invasive. It looks more insightful. It looks more accessible. CoMind leads this vital evolution.